INTENSIFICATION WITH INSULIN GLARGINE 300 U/ML (Gla-300) OR FIRST- GENERATION BASAL INSULINS (BIs) IN PEOPLE WITH TYPE 2 DIABETES (T2D) ON ONCE-WEEKLY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs): DELIVER NEW-G

被引：0

作者：

Umpierrez, G. ^{[1
]}

Bailey, T. ^{[2
]}

Mahieu, A. ^{[3
]}

Li, X. ^{[4
]}

Mabunay, M. A. ^{[5
]}

Fonseca, V ^{[6
]}

机构：

[1] Emory Univ, Sch Med, Atlanta, GA USA

[2] AMCR Inst, Escondido, CA USA

[3] Sanofi, Paris, France

[4] Sanofi, Bridgewater, NJ USA

[5] Sanofi, Singapore, Singapore

[6] Tulane Univ, Med Ctr, New Orleans, LA USA

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE139

引用

页码：S83 / S83

页数：1

共 50 条

[31] Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus
Billings, Liana K.
Handelsman, Yehuda
Heile, Michael
Schneider, Doron
Wyne, Kathleen
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (09): : S30 - S41
[32] Treatment and dosing patterns among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Europe
Norrbacka, K.
Divino, V.
DeKoven, M.
Boye, K. S.
DIABETOLOGIA, 2016, 59 : S387 - S388
[33] Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis
Weeda, Erin R.
Muraoka, Alyssa K.
Brock, Matthew D.
Cannon, Jessica M.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (09)
[34] Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis
Ayoub, Mark
Aibani, Rafi
Dodd, Tiana
Ceesay, Muhammed
Bhinder, Muhammad
Faris, Carol
Amin, Nisar
Daglilar, Ebubekir
CANCERS, 2024, 16 (18)
[35] Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Basal Insulins (BI) in Insulin-Naive Type 2 Diabetes (T2D) Patients (Pts) With and Without Cardiovascular Disease (CVD): Outcomes of the Randomized Pragmatic Real-Life Clinical Trial ACHIEVE Control
Frias, Juan P.
Evenou, Pierre
Dalton, David
Dungan, Kathleen M.
DIABETES, 2019, 68
[36] Insulin Glargine and SGLT2 Inhibitors Have Higher Risk of Major Adverse Cardiovascular Events (MACE) Compared with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in a National Cohort of Veterans with Type 2 Diabetes (T2D) and CKD
Katkam, Niharika
Sarwal, Amara
Hartsell, Sydney Elizabeth
Singh, Ravinder
Wei Guo
Boucher, Robert E.
Chakravartula, Akhil Ramanujam
Shen Jincheng
Nevers, Mckenna R.
Drakos, Stavros
Greene, Tom
Beddhu, Srinivasan
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
[37] SGLT2 Inhibitors Are Associated with Lower Risk of CKD Progression in Type 2 Diabetes (T2D) than Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs): An Emulated Clinical Trial
Hartsell, Sydney Elizabeth
Sarwal, Amara
Singh, Ravinder
Nevers, Mckenna R.
Shen Jincheng
Wei Guo
Boucher, Robert E.
Greene, Tom
Drakos, Stavros
Beddhu, Srinivasan
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
[38] Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
Fazeli, Sasan
Ehrhardt, Nicole
DIABETES, 2018, 67
[39] Identification by Multivariable Analysis of Predictive Factors of HbA1c Target Achievement in People with T2D Initiating Treatment with Insulin Glargine 300 U/mL (Gla-300)-REALI Pooled Database
Freemantle, Nick
Bigot, Gregory
Bonnemaire, Mireille
Mauricio, Didac
Bonadonna, Riccardo C.
Gourdy, Pierre
Ciocca, Alice
Mueller-Wieland, Dirk
DIABETES, 2019, 68
[40] Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins-Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL-The RESTORE-G Real-World Study
Candido, Riccardo
Nicolucci, Antonio
Larosa, Monica
Rossi, Maria Chiara
Napoli, Raffaele
DIABETES, 2023, 72

← 1 2 3 4 5 →